Clinical trials: Moderate to Severe Asthma
Asthma (Diagnosis), Breathlessness
Multicomponent Breathlessness and Physical Activity Intervention in People With Asthma Using a Digital Platform
Treating breathlessness could help people with asthma have fewer symptoms and be more physically active. People with asthma report that it is important to deal with breathlessness during physical activity programs, but past…
- Trial name
- BRAID (NCT07421115)
- Testing
- Multicomponent digital self-management platform, Enhanced usual care
- Where
- 2 sites in Australia
- Volunteers
- 300 people
- Sponsor
- University of Newcastle, Australia
Bronchial Asthma
Effect of Addition of Oral Montelukast to Standard Treatment in Acute Moderate to Severe Asthma in Children
Available evidences show a role of oral montelukast in acute asthma. Safety of oral montelukast is well established in children, as evidenced by use of oral montelukast in long term management of asthma.
- Trial name
- Montelukast (NCT00565955)
- Testing
- montelukast
- Where
- India
- Volunteers
- 116 people
- Sponsor
- All India Institute of Medical Sciences
Asthma
Pediatric Study to Evaluate Treatment of Persistent Moderate or Severe Asthma With the Association Fluticasone 250 mcg/Dose and Salmeterol 50 mcg/Dose - ADERE PROJECT
Prospective, parallel-group, randomized study to evaluate the compliance to the treatment of children aged between 6 and 14 years old with persistent moderate or severe asthma, receiving the association Fluticasone 250 mcg/dose…
- Trial name
- ADERE (Ped) (NCT01476059)
- Testing
- Telephone follow-up, No telephone follow-up
- Volunteers
- 472 people
- Sponsor
- GlaxoSmithKline
Moderate-to-Severe Asthma
Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids
This study will evaluate the safety, tolerability and efficacy of a single dose level of KB003 in subjects with inadequately controlled asthma.
- Trial name
- KB003-04 (NCT01603277)
- Testing
- Anti-GM-CSF Monoclonal Antibody 400mg
- Where
- 70 sites in United States, Australia and 4 more
- Volunteers
- 160 people
- Sponsor
- Humanigen, Inc.
Asthma
A Study to Evaluate the Efficacy and Safety of AK120 in the Treatment of Subjects With Moderate-to-severe Asthma
This is a randomized, double-blind, placebo-controlled, multicenter, phase II clinical study to evaluate the efficacy and safety of AK120 in the treatment of subjects with moderate-to-severe asthma.
- Trial name
- NCT05155020
- Testing
- AK120
- Where
- 19 sites in China
- Volunteers
- 1 people
- Sponsor
- Akeso
Asthma
Efficacy and Safety of Combivent® Aerosol and Spacer, in Adult Patients With Moderate to Severe Asthma Crisis
Study to evaluate the bronchodilator efficacy and safety of a fixed combination of salbutamol sulfate (120 mcg) + ipratropium bromide (20mcg) (Combivent® MDI) in aerosol plus spacer in adult patients with moderate-to-severe…
- Trial name
- NCT02182700
- Testing
- salbutamol sulfate + ipratropium bromide
- Volunteers
- 47 people
- Sponsor
- Boehringer Ingelheim
Asthma
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07275315) for the potential treatment of moderate-to-severe asthma.
- Trial name
- NCT06977581
- Testing
- PF-07275315
- Where
- 137 sites in United States, Argentina and 13 more
- Volunteers
- 252 people
- Sponsor
- Pfizer
Moderate to Severe Asthma
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function
- Trial name
- NCT05851443
- Testing
- povorcitinib, ICS-LABA
- Where
- 82 sites in United States, Argentina and 5 more
- Volunteers
- 247 people
- Sponsor
- Incyte Corporation
Asthma
An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma
The study proposes to evaluate the safety and efficacy of PF-03715455 in moderate to severe asthma when added to standard of care and during staged withdrawal of background therapy.
- Trial name
- NCT02219048
- Testing
- PF-03715455
- Where
- 28 sites in United States
- Volunteers
- 51 people
- Sponsor
- Pfizer
Asthma
Evaluating Effects of Curcumin in Moderate to Severe Asthmatics
The purpose of this investigator-initiated study is to evaluate the effects of oral curcumin supplementation versus placebo in adult patients with moderate to severe asthma.
- Trial name
- NCT04353310
- Testing
- Curcumin
- Sponsor
- Loma Linda University
Moderate to Severe Asthma
A Study of CM310 in Subjects With Moderate to Severe Asthma
This study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅱ/Ⅲ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM310 in subjects with moderate to severe…
- Trial name
- NCT05761028
- Testing
- CM310
- Where
- China
- Volunteers
- 600 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Asthma
Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma
This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, safety, and tolerability of add-on therapy with SC lunsekimig in adult participants…
- Trial name
- AIRCULES (NCT06102005)
- Testing
- Lunsekimig
- Where
- 156 sites in United States, Argentina and 12 more
- Volunteers
- 685 people
- Sponsor
- Sanofi
Asthma Bronchiale
An Open, Randomised, Parallel Group Multicentre Study to Compare the Efficacy and Safety of Flutiform® pMDI vs Fluticasone pMDI Plus Formoterol DPI in Adolescent and Adult Subjects With Mild to Moderate-severe Persistent, Reversible Asthma
Flutiform® compared with the individual components Flixotide® (Fluticasone) and Foradil® (Formoterol) in adolescent and adult patients.
- Trial name
- NCT00563056
- Testing
- Flutiform, Flixotide plus Foradil
- Where
- 6 sites in Germany, Hungary and 4 more
- Volunteers
- 227 people
- Sponsor
- Mundipharma Research Limited
Moderate to Severe Asthma
PULmonary Stimulation for Asthma Relief
This study aims to assess the safety and efficacy of Pulmonary Neuromodulation in patients suffering from moderate to severe asthma
- Trial name
- PULSAR (NCT07709754)
- Testing
- Spinal Cord Stimulation
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Spiro Medical, Inc.
Asthma
Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 Years
A double blind, double dummy, randomised, multicentre, two arm parallel group study to assess the efficacy and safety of FLUTIFORM® pMDI (2 puffs bid) vs Seretide® pMDI (2 puffs bid) in subjects aged ≥12 years with moderate to…
- Trial name
- NCT03387241
- Testing
- Fluticasone/ Formoterol, fluticasone/ salmeterol
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
Asthma, Healthy Volunteers
Evaluation of Safety, Side Effects, and How the Drug, Inhaled CHF10136, Is Absorbed, Modified and Removed From the Body in Healthy Adults and Adults With Asthma
This study evaluates the safety and tolerability of CHF10136 administered by inhalation in healthy adults and adults with asthma.
- Trial name
- NCT07851623
- Testing
- CHF10136
- Where
- 3 sites in United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
The purpose of this study is to provide safety and tolerability, pharmacokinetics and immunogenicity data for multiple CSJ117 doses inhaled once daily compared with placebo, in adult asthma participants treated with medium or…
- Trial name
- NCT04946318
- Testing
- CSJ117
- Where
- 58 sites in United States, Argentina and 12 more
- Volunteers
- 136 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma
To demonstrate that CHF 1535 via NEXT DPI (beclomethasone dipropionate + formoterol fumarate 100 + 6 μg), 1 inhalation or 2 inhalations twice daily, for 12 weeks is non-inferior to the corresponding dose of CHF 1535 via HFA-134a…
- Trial name
- NCT00862394
- Testing
- BDP/Formoterol Next DPI, Foster
- Where
- Germany
- Volunteers
- 783 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Nebulized Magnesium Sulfate in Pediatric Asthma
Nebulized Magnesium Sulfate has been shown to be of benefit in adults with acute asthma exacerbations, though limited work has been done in the pediatric population.
- Trial name
- NCT00522444
- Testing
- Nebulized Magnesium Sulfate, Nebulized normal saline
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Asthma
Withania Somnifera for Moderate-to-Severe Persistent Asthma
This randomized, double-blind, placebo-controlled study evaluated Withania somnifera root powder as a complementary therapy in adults with moderate-to-severe persistent asthma receiving standard asthma treatment.
- Trial name
- WISTA (NCT07787507)
- Testing
- Withania somnifera Root Powder, Standard Asthma Treatment
- Where
- India
- Volunteers
- 120 people
- Sponsor
- Aligarh Muslim University